Scancell Holdings plc
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer, has raised £7.5 million through an institutional placing of shares.
LGB Corporate Finance worked closely with the company and its corporate broker, Panmure Gordon, to extend distribution of the issue to a number of wealth management, family office and private investors.
The proceeds of the placing will be used to commence scheduled trials of a vaccine addressing late stage melanoma, support the Cancer Research UK development of the company vaccine against non-small-cell lung carcinoma, commence a first in-human study in patients with triple-negative breast cancer, further the company’s collaboration with BioNTech and initiate a pre-clinical development programme for oesophageal, gastric, pancreatic and colorectal cancers. These projects demonstrate the broadening scope of the company’s business and its collaborations with tier-1 counterparties in the immuno oncology sector.